


Stock Selection Guide

Company	Vertex Pharmaceuticals		Date	05/06/22	
Prepared by	FWIC		Data taken from	BI Stock Data	
Where traded	NAS	Industry	Biotechnology		
Capitalization --- Outstanding Amounts	Reference				
Preferred (\$M)	0.0	% Insiders	% Institution		
Common (M Shares)	257.0		1.0	99.8	
Debt (\$M)	934.1	% to Tot Cap	8.5	% Pot Dil	1.0

Symbol: VRTX

1 VISUAL ANALYSIS of Sales, Earnings, and Price



- | | | | |
|-----------------------------------|-------|--|--------|
| (1) Historical Sales Growth | 26.9% | (3) Historical Earnings Per Share Growth | 285.5% |
| (2) Estimated Future Sales Growth | 10.0% | (4) Estimated Future Earnings Per Share Growth | 10.2% |

2 EVALUATING Management

Vertex Pharmaceutica

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Last 5 Year Avg.
Pre-tax Profit on Sales	-0.8%	-80.5%	-126.6%	-54.0%	-4.0%	-0.6%	19.7%	33.5%	50.2%	36.0%	27.8%
% Earned on Equity	-10.9%	-36.6%	-65.7%	-61.7%	-11.2%	14.7%	71.0%	22.2%	32.9%	24.1%	33.0%
% Debt To Capital	41.1%	27.2%	43.4%	46.8%	42.1%	23.0%	11.8%	9.7%	9.7%	8.5%	12.5%

3 PRICE-EARNINGS HISTORY as an indicator of the future

This shows how stock prices have fluctuated with earnings and dividends. It is building block for translating earnings into future stock prices.

CLOSING PRICE 235.00 (05/06/22)

HIGH THIS YEAR 292.75

LOW THIS YEAR 176.36

	A	B	C	D	E	F	G	H
Year	Price		Earnings	Price Earnings Ratio		Dividend	% Payout	% High Yield
	High	Low	Per Share	High A / C	Low B / C	Per Share	F / C * 100	F / B * 100
2017	167.9	73.3	1.04	161.4	70.5	0.00	0.0	0.0
2018	193.8	144.1	8.09	24.0	17.8	0.00	0.0	0.0
2019	225.7	161.0	4.51	50.0	35.7	0.00	0.0	0.0
2020	306.1	197.5	10.29	29.7	19.2	0.00	0.0	0.0
2021	243.0	176.4	9.01	27.0	19.6	0.00	0.0	0.0
AVERAGE		150.4		26.9	18.9		0.0	
CURRENT/TTM			9.03			0.00	0.0	
AVERAGE PRICE EARNINGS RATIO: 22.9				CURRENT PRICE EARNINGS RATIO: 26.0				

4 EVALUATING RISK and REWARD over the next 5 years

Assuming one recession and one business boom every 5 years, calculations are made of how high and how low the stock might sell. The upside-downside ratio is the key to evaluating risk and reward.

A HIGH PRICE - NEXT 5 YEARS

Avg. High P/E 27.0 X Estimate High Earnings/Share 14.64 = Forecasted High Price \$ 395.4

B LOW PRICE - NEXT 5 YEARS

(a) Avg. Low P/E 19.6 X Estimate Low Earnings/Share 9.03 = Forecasted Low Price \$ 177.0

(b) Avg. Low Price of Last 5 Years 150.4

(c) Recent Market Low Price 176.4

(d) Price Dividend Will Support $\frac{\text{Indicated Dividend}}{\text{High Yield}} = \frac{0.00}{0.00\%} = 0.0$

Selected Forecasted Low Price \$ 177.0

C ZONING using 25%-50%-25%

Forecasted High Price 395.4 Minus Forecasted Low Price 177.0 = 218.4 Range. 25% of Range 54.6

Buy Zone 177.0 to 231.6

Hold Zone 231.6 to 340.8

Sell Zone 340.8 to 395.4

Present Market Price of 235.00 is in the **HOLD** Zone

D UPSIDE DOWNSIDE RATIO (POTENTIAL GAIN VS. RISK OR LOSS)

$\frac{\text{High Price } 395.4 - \text{Present Price } 235.00}{\text{Present Price } 235.00} = \frac{160.36}{235.00} = 0.6824$
 $\frac{\text{Present Price } 235.00 - \text{Minus Low Price } 177.0}{\text{Present Price } 235.00} = \frac{58.00}{235.00} = 0.2468$
 Ratio = $\frac{0.6824}{0.2468} = 2.8$ To 1

E PRICE TARGET (Note: This shows the potential market price appreciation over the next five years in simple interest terms.)

$\frac{\text{High Price } 395.4}{\text{Closing Price } 235.00} = 1.6824 \times 100 = 168.24 - 100 = 68.2\%$ % Appreciation

5 5-YEAR POTENTIAL

This combines price appreciation with dividend yield to get an estimate of total return. It provides a standard for comparing income and growth stocks.

A $\frac{\text{Indicated Annual Dividend } 0.00}{\text{Closing Price } 235.00} = 0.0000 = 0.0\%$ Current Yield

B AVERAGE YIELD - USING FORECAST HIGH P/E

$\frac{\text{Avg. \% Payout } 0.0\%}{\text{Forecast High PE } 27.00} = 0.0\%$

AVERAGE YIELD - USING FORECAST AVERAGE P/E

$\frac{\text{Avg. \% Payout } 0.0\%}{\text{Forecast Average PE } 23.30} = 0.0\%$

C COMPOUND ANNUAL RETURN - USING FORECAST HIGH P/E

Annualized Appreciation 11.0 %
 Average Yield 0.0 %
 Annualized Rate of Return 11.0 %

COMPOUND ANNUAL RETURN - USING FORECAST AVG P/E

Annualized Appreciation 7.7 %
 Average Yield 0.0 %
 Annualized Rate of Return 7.7 %


Notes: VRTX 5/9/22_Arvind K

Date	Subject	Description	Type
04/01/22	Pipeline	Vertex is making headway with a number of mid- or late-stage studies addressing such serious illnesses and conditions as sickle cell disease, beta thalassemia, Type 1 diabetes, kidney disease, pain, and protein deficiencies. The programs include Phase I/II clinical trial of VX-880, a stem cell-derived replacement therapy for Type 1 diabetes, and ongoing late-stage clinical trials on CTX001 for beta thalassemia and sickle cell disease, in collaboration with CRISPR Therapeutics	Community
04/01/22	Valueline Comment on 2021 Results	Big gains in the CF product portfolio, led by Trikafta/Kaftrio, catapulted revenues by 22% in 2021; EPS would have been higher were it not for a \$900 million payment to CRISPR Therapeutics under an amended R&D collaboration. EPS in 2021 was down 12% from 2020.. Valueline thinks EPS will be \$12.00 in 2022, \$13 in 2023 and \$16 in 5 years.	Community
02/07/22	VRTX SHARES ARE UP at the end of 4thQtr	In 2022, Analysts' expect VRTX's revenues to increase 12% Y/Y to \$8.5 billion after growing 22% Y/Y in 2021, which is largely attributable to the incredibly successful launch of Trikafta in late 2019. In the 4th quarter of 2021, Trikafta accounted for 82% of VRTX's product sales. Value Line (Dec 03 - 2021) sales growth estimates for LT (24-26) are Revenue 10,000 (\$mil) and for EPS Growth for LT (24-26) are 15.5 These figures were taken into account in developing SSG: In forecasting sales growth (11%) and EPS growth (11.2%).	Community
08/01/21	Vertex not doing very well	The past two years has shown a significant drop in the value of the company's stock. We need more specific information about its potential to increase its value. SSG says it will happen but this is a pharmaceutical company and they are totally dependent on the success of the drugs in their development line.	Community
06/13/21	Another possible drug abandoned	Abandoning further development of VX-864 for alpha-1 antitrypsin deficiency ("AATD") made the stock price drop about 10% overnight.	Community
01/03/21	One time adjustments and non-GAAP data etc	1) One time non-recurring tax adjustments for the year 2018 annual EPS is adjusted from \$8.09 to \$2.06. Quarter Q3 is adjusted from \$0.00 to \$-0.05 2) Income tax rates for yrs 2012 thru 2017 with negative earnings are made 0 in the Annual Data 3) Valuline 5-yr estimate for Revenue & EPS added in yr 2024 yr in "Data" -> "Detailed Estimates" 4) P/E data for the year 2018 is discounted in addition to the "NMF" data for 2015 thru 2017 yrs	Community

10/21/20	Halt in VX drug	VX-814 due to causing liver toxicity has dropped value of stock substantially. VRTX hasn't much on the horizon and a bad record for making acquisitions. If a good acquisition by VRTX becomes available in 2021 I would look very hard at this company if the price is around 200.00	Community
10/20/20	VRTX still showing growth and a buy	Using a Sales and EPS growth of 10% which is very conservative as of this date the stock is presently in the buy with a ridiculous up to down ratio of 10 to 1. Eliminated PE Ratios High/Low of 2017 which were outliers in Valuation and Return and used the resulting average.	Community

Quarterly Growth Trend Data

Graph: Trailing 4 Quarters, Last 5 Years of Data



Quarterly Data									Last 12 Months Data								
Period	EPS		Pre-Tax Profit			Sales		Income Tax Rate	EPS	Pre-Tax Profit		Sales	Income Tax		%Change		
	\$	%Change	\$ Mil	%Sales	%Change	\$ Mil	%Change	\$		\$ Mil	%Sales	\$ Mil	%Rate	EPS	Pre-Tax Profit	Sales	
12/21	3.00	30.4	871.0	42.0	-2.0	2,072.6	27.3	11.6	9.03	2,730.4	36.0	7,574.4	2,078.9	76.1	-12.3	-12.4	22.1
09/21	3.28	29.6	1,082.7	54.6	45.2	1,984.2	29.0	21.3	8.33	2,748.1	38.5	7,129.7	2,232.7	81.2	-18.6	-5.4	19.0
06/21	0.26	-91.8	-44.3	-2.5	-105.4	1,793.4	17.6	251.2	7.58	2,411.2	36.1	6,683.8	1,893.9	78.5	-4.3	8.1	23.7
03/21	2.49	8.7	821.0	47.6	24.9	1,724.3	13.8	20.4	10.50	3,280.2	51.1	6,414.9	503.9	15.4	82.0	89.4	33.1
12/20	2.30	3.1	888.6	54.6	31.3	1,627.8	15.2	32.0	10.30	3,116.8	50.2	6,205.7	384.5	12.3	128.4	123.4	49.1
09/20	2.53	1,050.0	745.9	48.5	955.5	1,538.3	62.0	10.5	10.23	2,905.1	48.5	5,991.1	226.4	7.8	24.0	287.1	65.5
06/20	3.18	208.7	824.8	54.1	152.1	1,524.5	62.0	-1.5	7.92	2,229.9	41.3	5,402.7	218.9	9.8	-7.2	173.2	56.4

Quarterly Growth Trend Data

Graph: Trailing 4 Quarters, Last 5 Years of Data

Quarterly Data									Last 12 Months Data										
Period	EPS		Pre-Tax Profit			Sales		Income Tax Rate	EPS	Pre-Tax Profit			Sales	Income Tax			%Change		
	\$	%Change	\$ Mil	%Sales	%Change	\$ Mil	%Change			\$	\$ Mil	%Sales		\$ Mil	%Rate	EPS	Pre-Tax Profit	Sales	
03/20	2.29	122.3	657.5	43.4	105.4	1,515.1	76.5	8.3	5.77	1,732.3	35.9	4,819.5	255.6	14.8	-30.5	145.4	47.6		
12/19	2.23	-62.6	677.0	47.9	1,983.1	1,413.3	62.4	13.8	4.51	1,394.9	33.5	4,162.8	233.0	16.7	-44.2	132.4	36.6		
09/19	0.22	-56.0	70.7	7.4	-48.2	949.8	21.1	18.6	8.25	750.5	20.7	3,619.7	-8,517.9	-1,135.0	230.0	10.3	27.9		
06/19	1.03	28.8	327.1	34.8	51.0	941.3	25.1	18.3	8.53	816.3	23.6	3,454.4	-9,291.2	-1,138.2	436.5	545.3	31.7		
03/19	1.03	27.2	320.2	37.3	49.2	858.4	34.0	16.1	8.30	705.8	21.6	3,265.2	-8,056.8	-1,141.6	865.1	1,393.1	35.2		
12/18	5.97	1,430.8	32.5	3.7	-71.1	870.1	33.5	-4,593.0	8.08	600.2	19.7	3,047.6	-6,885.2	-1,147.1	676.9	3,925.9	22.5		
09/18	0.50	222.0	136.5	17.4	132.7	784.5	35.7	5.9	2.50	680.2	24.0	2,829.1	23.6	3.5	220.5	730.8	23.2		
06/18	0.80	1,042.9	216.6	28.8	510.0	752.2	38.2	4.8	1.59	126.5	4.8	2,622.8	12.1	9.5	54.4	-53.2	23.1		
03/18	0.81	-18.2	214.6	33.5	-15.3	640.8	-10.3	-5.9	0.86	-54.6	-2.3	2,414.7	-6.2	11.4	22.9	-125.2	19.6		
12/17	0.39	200.0	112.4	17.3	453.7	651.6	42.1	9.1	1.04	-15.7	-0.6	2,488.7	-2.1	13.3	326.1	76.7	46.2		
09/17	-0.41	-156.3	-417.2	-72.2	-968.7	578.2	39.7	30.2	0.78	-107.8	-4.7	2,295.7	-2.0	1.8	186.7	34.1	38.2		
06/17	0.07	126.9	35.5	6.5	297.0	544.1	26.1	12.2	1.03	270.3	12.7	2,131.3	-16.4	-6.1	191.2	224.5	36.8		
03/17	0.99	682.4	253.5	35.5	928.1	714.7	79.5	1.6	0.70	216.8	10.7	2,018.8	-74.3	-34.3	142.4	155.6	56.3		
12/16	0.13	141.9	20.3	4.4	126.7	458.7	9.8	-36.7	-0.46	-67.4	-4.0	1,702.2	26.4	-39.1	80.1	87.9	64.9		
09/16	-0.16	59.0	-39.0	-9.4	57.8	413.8	33.6	-1.3	-0.90	-163.7	-9.9	1,661.4	48.3	-29.5	67.2	75.2	118.9		
06/16	-0.26	66.7	-18.0	-4.2	90.6	431.6	159.9	-100.6	-1.13	-217.2	-13.9	1,557.4	64.1	-29.5	63.2	70.4	147.9		
03/16	-0.17	79.5	-30.6	-7.7	84.6	398.1	187.4	-17.9	-1.65	-390.0	-30.2	1,291.9	32.5	-8.3	44.4	44.5	115.1		
12/15	-0.31	58.1	-76.0	-18.2	57.4	417.9	189.1	1.8	-2.31	-557.8	-54.0	1,032.3	21.7	-3.9	26.4	24.2	77.9		
09/15	-0.39	45.8	-92.5	-29.9	44.5	309.8	73.1	-1.4	-2.74	-660.3	-87.0	759.0	30.6	-4.6	-24.0	26.4	-3.6		
06/15	-0.78	-14.7	-190.9	-114.9	-20.3	166.1	20.0	-15.8	-3.07	-734.4	-116.9	628.1	35.1	-4.8	-51.2	14.6	-24.3		
03/15	-0.83	17.0	-198.4	-143.2	14.4	138.5	16.9	-0.2	-2.97	-702.3	-117.0	600.5	6.6	-0.9	-84.5	8.2	-40.1		
12/14	-0.74	-489.5	-178.6	-123.5	47.5	144.6	-58.8	-1.1	-3.14	-735.5	-126.7	580.4	7.3	-1.0	-53.9	24.6	-52.1		
09/14	-0.72	-33.3	-166.6	-93.1	-28.7	179.0	-19.3	-2.1	-2.21	-897.2	-114.0	787.0	-96.3	10.7	14.3	-25.2	-34.1		
06/14	-0.68	-161.5	-158.7	-114.6	-149.9	138.4	-55.5	-0.4	-2.03	-860.0	-103.6	829.7	-97.9	11.4	12.1	-45.2	-36.6		
03/14	-1.00	30.1	-231.7	-195.6	47.7	118.5	-63.9	-0.4	-1.61	-764.8	-76.3	1,002.1	-93.3	12.2	31.8	-40.8	-29.3		
12/13	0.19	154.3	-340.3	-96.9	-321.3	351.2	5.1	45.8	-2.04	-976.1	-80.5	1,212.0	-191.8	19.6	-308.0	-7,784.0	-20.6		
09/13	-0.54	-100.0	-129.4	-58.4	-2,431.6	221.7	-34.0	0.6	-2.58	-716.6	-60.0	1,194.8	-64.8	9.0					
06/13	-0.26	16.1	-63.5	-20.4	-340.9	310.8	-25.7	2.8	-2.31	-592.3	-45.2	1,309.1	565.9	-95.5					
03/13	-1.43	-432.6	-442.9	-134.9	-603.9	328.4	-25.2	29.4	-2.36	-543.2	-38.3	1,416.7	712.0	-131.1					
12/12	-0.35		-80.8	-24.2		334.0		3.3											
09/12	-0.27		-5.1	-1.5		336.0		-417.7											

Quarterly Growth Trend Data

Graph: Trailing 4 Quarters, Last 5 Years of Data

Quarterly Data									Last 12 Months Data								
Period	EPS		Pre-Tax Profit			Sales		Income Tax Rate	EPS	Pre-Tax Profit		Sales	Income Tax		%Change		
	\$	%Change	\$ Mil	%Sales	%Change	\$ Mil	%Change	\$		\$ Mil	%Sales		\$ Mil	%Rate	EPS	Pre-Tax Profit	Sales
06/12	-0.31		-14.4	-3.4		418.3		-139.3									
03/12	0.43		87.9	20.0		438.7		0.0									